Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26521676 | 0.84 | SLC22A12 (0.46) | SLC22A12PIK3CAPTGS1PTGS2NPC1 | |
| SCHEMBL16926830 | 0.83 | PIK3C3 (0.48) | PIK3C3SLC22A12PIK3CANPC1ALDH1A1 | |
| SCHEMBL3095677 | 0.82 | PIK3C3 (0.51) | PIK3C3PIK3CAPTGS1PTGS2NPC1 | |
| SCHEMBL24576532 | 0.81 | PIK3C3 (0.48) | PIK3C3PIK3CAPTGS1PTGS2PIK3CD | |
| SCHEMBL16914051 | 0.81 | PIK3C3 (0.47) | PIK3C3PIK3CANPC1ALDH1A1MEN1 | |
| SCHEMBL856790 | 0.81 | SLC22A12 (0.44) | SLC22A12PIK3CAPTGS1PTGS2NPC1 | |
| SCHEMBL857830 | 0.81 | NPC1 (0.49) | SLC22A12PIK3CAPTGS1PTGS2NPC1 | |
| SCHEMBL458986 | 0.81 | PIK3CA (0.60) | PIK3C3SLC22A12PIK3CAPTGS1PTGS2 | |
| SCHEMBL858032 | 0.79 | SLC22A12 (0.43) | SLC22A12PIK3CAPTGS1PTGS2NPC1 | |
| SCHEMBL23362710 | 0.79 | PIK3C3 (0.46) | PIK3C3SLC22A12PIK3CAPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| EP-2668178-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2668178-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2167092-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009055418-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | PIK3C3 27/4885SLC22A12 3959/4885PIK3CA 18/4885 |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3C3 55/4885SLC22A12 1280/4885PIK3CA 3/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3C3 43/4885SLC22A12 1414/4885PIK3CA 3/4885 |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | PIK3C3 27/4885SLC22A12 3959/4885PIK3CA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.